CAR T

Natural killer cells can sometimes attack beneficial CAR T cell immunotherapies. Now, researchers have discovered why and a potential way to stop them.

A modular CAR T cell could make cancer therapy safer and more effective.

Rheumatologist James Chung leads efforts to expand CAR T cell therapy beyond the oncology field.

Mycologists programmed immune cells to attack Aspergillus fumigatus, a common infectious species rapidly growing resistant to antifungals.